Company profile for Apogenix

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Apogenix develops innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response in cancer patients and reducing lymphopenia and inflammatory cell death in patients with viral infections.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Im Neuenheimer Feld 584, 69120 Heidelberg,
Telephone
Telephone
+49 6221 58608-0
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

CGT Asia

Not Confirmed

envelop Contact Supplier

CGT Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmatimes.com/news/apogenixs_asunercept_demonstrates_efficacy_in_covid-19_trial_1456969

PHARMATIMES
19 Oct 2022

https://uk.finance.yahoo.com/news/apogenix-receives-eur-20-7-090007056.html

YAHOO
09 Dec 2021

http://www.pharmabiz.com/NewsDetails.aspx?aid=134352&sid=2

PHARMABIZ
23 Dec 2020

http://www.pharmabiz.com/NewsDetails.aspx?aid=134352&sid=2

PHARMABIZ
23 Dec 2020

https://uk.finance.yahoo.com/news/apogenix-advances-clinical-development-cd95l-080002143.html

YAHOO
13 Oct 2020

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty